Abstract
In order to evaluate blood coagulation and fibrinolysis in diabetics, especially in regard to diabetic retinopathy and blood glucose control, thrombin-antithrombin III-complex (TAT) and ce2-plasmin inhibitor-plasmin-complex (PIC) were measured. TAT and PIC in 264 diabetic patients and 66 healthy people used as normal controls showed the following changes.
(1) TAT and PIC were significantly higher in diabetic patients in general (TAT: 2.52μg/l, PIC: 1.28μg/ml) than in normal controls (TAT: 1.72μg/l, PIC: 1.09μg/ml). (2) TAT became significantly higher as retinopathy worsened. (3) Both TAT and PIC showed high values in patients with proliferative retinopathy (TAT: 3.53μg/l, PIC: 1.43μg/ml) and in patients whose retinopathy was progressive (TAT: 3.07μg/l, PIC: 1.56μ/ml)(4) Both TAT and PIC showed high values in patients with improving blood glucose control (TAT: 3.55μg/l, PIC: 1.47 μg/ml). Among patients with improving blood glucose control, TAT was slightly higher and PIC was significantly higher in patients whose retinopathy was progressive (TAT: 3.53μg/l, PIC: 1.93μg/ml) than in patients whose retinopathy was not progressive (TAT: 3.24μg/l, PIC: 1.36μg/ml) Considering the above results, diabetic complications, especially the progress of retinopathy, and increases in TAT and PIC seem to be closely related, and it is conceivable that changes in bloodcoagulation and fibrinolysis along with blood glucose control, affect the progress of retinopathy.
